

MedVector Corp



ANNUAL REPORT

898 N. Pacific Coast Highway

El Segundo , CA 90245

(310) 869-3100

<https://medvectortrials.com/>

This Annual Report is dated April 24, 2021.

BUSINESS

MedVector is the only company creating access to subjects beyond approved clinical trial sites. By unlocking patients trapped behind non-participating physicians and unapproved site locations, we create access to millions of new subject-candidates for clinical trials. We partner with CROs, sponsors, and existing patient recruitment companies to connect subjects beyond geographic and socioeconomic barriers, improving diversity and eliminating subject enrollment delays.

MedVector connects these out-of-reach subjects to existing, approved, clinical trial sites using our proprietary hardware/software combo called Prime-Control Technology. Our turnkey solution works within the existing protocol, without triggering new sites. Principal Investigators can now monitor these trapped subjects live, face-to-face, like they're in the same room.

Previous Offerings

Between 2020 and 2019, we sold 301,627 shares of common stock in exchange for \$1.619562 per share under Regulation Crowdfunding.

Type of security sold: Convertible Note

Final amount sold: \$600,000.00

Use of proceeds: Concept development, hospital network, legal pathways, partnership development, product design, operational expenses.

Date: April 15, 2018

Offering exemption relied upon: Section 4(a)(2)

Name: Preferred Stock

Type of security sold: Equity

Final amount sold: \$249,999.37

Number of Securities Sold: 255,780

Use of proceeds: Build device

Date: July 17, 2019

Offering exemption relied upon: Section 4(a)(2)

REGULATORY INFORMATION

The company has not previously failed to comply with the requirements of Regulation Crowdfunding;

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATION

Operating Results – 2020 Compared to 2019

- How long can the business operate without revenue:

We are raising to fund our launch. The cash balances plus crowdfund commitments gives us 5-7 months of runway.

- Foreseeable major expenses based on projections:

We've already built the majority of our tech. Still have about 10% in refinements and backend development. Our largest expense during our launch will be employee payroll & consulting fee expenses during our trial phase.

- Future operational challenges:

This is a challenging industry to bootstrap. A clinical study could last 1 year, so even if we launch with only a few subjects, we would need to stay operational throughout the entire study.

Because of this, access to capital is necessary to launch and scale. The good news is we have several VC's interested in funding our Series A once we have proven ourselves with some revenue.

- Future challenges related to capital resources:

Capital for devices, working capital for employee and operational expenses.

- Future milestones and events:

First we need to secure trial contracts, during which we plan to prove out our business concept.

Once we secure contracts with our CRO and Pharma contacts we will group as many subjects together at specific partner locations and begin generating revenue.

After proving our process to Pharma we plan to utilize the results of the early successes to pitch VC investors for Series A funding, to be used to scale the business.

Liquidity and Capital Resources

At December 31, 2020, the Company had cash of \$170,947.00. [*The Company intends to raise additional funds through an equity financing.*]

Debt

Creditor: Individual

Amount Owed: \$225,000.00

Interest Rate: 2.16%

Maturity Date: December 31, 2025

DIRECTORS, EXECUTIVE OFFICERS AND SIGNIFICANT EMPLOYEES

Our directors and executive officers as of the date hereof, are as follows:

Name: Scott Stout

Scott Stout's current primary role is with the Issuer.

Positions and offices currently held with the issuer:

Position: CEO & Co-Founder

Dates of Service: June 06, 2017 - Present

Responsibilities: Build, operate, and scale MedVector.

Other business experience in the past three years:

Employer: Wells Fargo Private Bank

Title: Financial Advisor

Dates of Service: October 01, 2014 - April 15, 2018

Responsibilities: Wealth Management, Options Strategist, Team Ops

Employer: CleanBox Tech

Title: Board Member

Dates of Service: January 01, 2018 - September 15, 2019

Responsibilities: Advising on business aspects, market, and product fit.

Name: Ted Barduson

Teds primary role is with MedVector .

Positions and offices currently held with the issuer:

• Position: COO and Co-Founder

Dates of Service: July 01, 2017 - Present

Responsibilities: Securing initial contracts, building teams, processes and systems to ensure service delivery.

Other business experience in the past three years:

Executive Advisor for Carrus/Career Step

Company Name Carrus

Dates Employed 2020

Employment Duration less than a year

Location Lehi, Utah, United States

Lead and coordinate mission-critical business initiatives for the Carrus Executive Team.

Responsibilities include assisting in the transition of the company and customers associated with Panacea Healthcare Solutions' company sale.

- Implemented financial modeling analytics model measuring health system turnover rate to drive new hire process improvements with new mobile, at home employee.
- Carrus Education Advisory Board to identify data-driven relationship management scoring to increase health system partnership and Carrus customer retention/expansion.

President and General Manager, formerly a Career Step Company

Company Name Panacea Healthcare Solutions Full-time

Dates Employed 2018 – 2020

Employment Duration 2 yrs

Location St Paul, Minnesota, United States

Led high performing staff of 40 to manage operational activities of three business units- value \$7.5M annual revenues; Increased recurring revenue from 27% to 59% while partnering with educational services of \$60+M from Career Step with 150 employees. Led to the sale of Panacea Healthcare Solutions

Hands on customer-facing collaboration with six directors across all business units/functions, including HR, finance, customer service, business development, sales, marketing, and R&D/software engineering management. Restructuring of vision and strategic direction to reposition each division as a differentiated competitor in the market.

SELECTED CONTRIBUTIONS:

- Delivered newly defined recurring revenue vision and mission and strategy to current customers while adding 100+ new hospital customer acquisition, including Kaiser Health, Baylor Scott and White Health System, and Montefiore Sloan Kettering as referenceable strategic account
- Presented care plan analysis model to drive customer experience and employee accountability to mutually beneficial metrics.
- Coaching direct reports to re-engineer resource allocation expense control to mirror 85% consultant utilization via innovative project management and relationship building POD structure
- Evangelized corporate strategy with a tour of 3 field offices and 110+ customers.

Name: Ian Leaman

Ian is a Director of the Company and serves as it's factional/ part-time CFO.

• Position: Director and Part-time CFO

Dates of Service: November 2020 - Present

Responsibilities: Financial control, back-office set-up, fundraising support.

Other business experience in the past three years:

Member Board Of Directors

Company Name: Legion Creative Group

Dates Employed Aug 2019 – Present

Employment Duration 1 yr 9 mos

Location Greater Los Angeles Area

Legion Creative is a Hollywood based creative agency, working across the entertainment and brand sectors. It creates and produces posters to promote movies & TV shows

Managing Director

Company Name CREO | MONTMINY & Co.

Dates Employed Nov 2018 – Dec 2019

Employment Duration 1 yr 2 mos

Location Los Angeles

M&A advisory investment bank in Los Angeles

PRINCIPAL SECURITY HOLDERS

Set forth below is information regarding the beneficial ownership of our Common Stock, our only outstanding class of capital stock, as of December 31, 2020, by (i) each person whom we know owned, beneficially, more than 10% of the outstanding shares of our Common Stock, and (ii) all of the current officers and directors as a group. We believe that, except as noted below, each named beneficial owner has sole voting and investment power with respect to the shares listed. Unless otherwise indicated herein, beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission and includes voting or investment power with respect to shares beneficially owned.

Title of class: Common Stock

Stockholder Name: Scott Stout

Amount and nature of Beneficial ownership: 4,249,500

Percent of class: 80.15

RELATED PARTY TRANSACTIONS

Name of Entity: Groves Family Holdings

Names of 20% owners: Kay Stout

Relationship to Company: Family member

Nature / amount of interest in the transaction: This is a credit line from a third party secured by the CEO's mothers' investment account.

Material Terms: The loan is attached to a credit line with an adjustable interest rate, currently 2.14%. There is no current maturity to the loan. Once paid back MedVector will still have access to this credit line until MedVector has the credit history to open it's own line.

OUR SECURITIES

Our authorized capital stock consists of 10,000,000 shares of Common Stock, par value \$0.0001 per share. As of December 31, 2020, 5,301,872 shares of Common stock are Outstanding. In addition 828,802 shares of Common Stock are reserved pursuant to an Option Pool.

The following is a summary of the rights of our capital stock as provided in our certificate of incorporation and bylaws.

ARTICLE 3

Stock

3.1 Certificates: Certificates of stock must be issued in numerical order. Each shareholder is entitled to a certificate signed by the President or a Vice President and the Secretary or Assistant Secretary. The certificate may be sealed with the Corporation's seal or a facsimile thereof. If an officer who has signed or whose facsimile signature appears on any stock certificate ceases to be an officer before the certificate is used, it may be issued by the Corporation and is valid as if the person were an officer on the date of issue.

3.2 Transfer: Transfers of stock must be made upon the corporation's stock transfer books. Stock transfer books must be kept at the Corporation's registered office, its principal place of business, or the office of its transfer agent or registrar. Before a new certificate is issued, the old certificate must be surrendered for cancellation. The Board of Directors may, by resolution, open a share register in any state of the United States, and may employ an agent or agents to keep such register, and to record transfers or shares therein.

3.3 Registered Owner: Shareholders will be treated by the corporation as the holders in fact of the stock registered in his or her name. The Corporation is not bound to recognize any equitable or other claim to or interest in any share on the part of any other person, except as expressly provided below or by the laws of the State of Delaware. The Board of Directors may resolve to adopt a procedure by which a shareholder of the Corporation may certify in writing to the Corporation that all or a portion of the shares registered in the shareholder's name are held for the account of a specified person or persons. The resolution must set forth:

- (a) The classification of shareholder who may certify;
- (b) The purpose or purposes for which the certification may be made;
- (c) The form of certification and information to be contained therein;
- (d) If the certification is with respect to a record date or closing of the stock transfer books, the date within which the certification must be received by the Corporation; and
- (e) Other provisions with respect to the procedure as are deemed necessary or desirable.

Upon receipt of a certification complying with this procedure, the Corporation must treat the persons specified in the certification as the

3 Corporate Bylaws

De l a w a r e holders of record of the number of shares specified in place of the shareholder making the certification.

3.4 Mutilated, Lost, or Destroyed Certificates: In case of any mutilation, loss or destruction of any stock certificate, another may be issued in its place on proof of such mutilation, loss or destruction. The Board of Directors may impose conditions on such issuance and may require the giving of a satisfactory bond or indemnity to the Corporation or the board may establish other procedures as they deem necessary.

3.5 Fractional Shares or Scrip: The Corporation may:

(a) Issue fractions of a share which entitle the holder to exercise voting rights, to receive dividends, and to participate in any of the Corporation's assets in the event of liquidation;

(b) Arrange for the disposition of fractional interests by those entitled thereto;

(c) Pay the fair market value, in cash, of fractions of a share as of the time when those entitled to receive such shares are determined; or

(d) Issue scrip in registered or bearer form which entitles the holder to receive a certificate for the full share upon surrender of such scrip aggregating a full share.

3.6 Shares of Another Corporation: Shares owned by the Corporation in another corporation, domestic or foreign, may be voted by officer, agent or proxy chosen by the Board of Directors or, in the absence of such determination, by the President of the Corporation.

What it means to be a minority holder

As a minority holder you will have limited ability, if at all, to influence our policies or any other corporate matter, including the election of directors, changes to our company's governance documents, additional issuances of securities, company repurchases of securities, a sale of the company or of assets of the company or transactions with related parties.

Dilution

Investors should understand the potential for dilution. The investor's stake in a company could be diluted due to the company issuing additional shares. In other words, when the company issues more shares, the percentage of the company that you own will decrease, even though the value of the company may increase. You will own a smaller piece of a larger company. This increase in number of shares outstanding could result from a stock offering (such as an initial public offering, another crowdfunding round, a venture capital round or angel investment), employees exercising stock options, or by conversion of certain instruments (e.g. convertible notes, preferred shares or warrants) into stock.

If we decide to issue more shares, an investor could experience value dilution, with each share being worth less than before, and control dilution, with the total percentage an investor owns being less than before. There may also be earnings dilution, with a reduction in the amount earned per share (though this typically occurs only if we offer dividends, and most early stage companies are unlikely to offer dividends, preferring to invest any earnings into the company).

The type of dilution that hurts early-stage investors most occurs when the company sells more shares in a "down round," meaning at a lower valuation than in earlier offerings.

If you are making an investment expecting to own a certain percentage of the company or expecting each share to hold a certain amount of value, it's important to realize how the value of those shares can decrease by actions taken by the company. Dilution can make drastic changes to the value of each share, ownership percentage, voting control, and earnings per share.

RESTRICTIONS ON TRANSFER

The common stock sold in the Regulation CF offering, may not be transferred by any purchaser, for a period of one-year beginning when the securities were issued, unless such securities are transferred:

- (1) to the Company;
- (2) to an accredited investor;
- (3) as part of an offering registered with the SEC; or
- (4) to a member of the family of the purchaser or the equivalent, to a trust controlled by the purchaser, to a trust created for the benefit of a member of the family of the purchaser or the equivalent, or in connection with the death or divorce of the purchaser or other similar circumstance.

SIGNATURES

Pursuant to the requirements of Sections 4(a)(6) and 4A of the Securities Act of 1933 and Regulation Crowdfunding (§ 227.100-503), the issuer certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form C and has duly caused this Form to be signed on its behalf by the duly authorized undersigned, on April 24, 2021.

MedVector Corp

By */s/ Ian Leaman*

Name: Ian Leaman

Title: Chief Executive Officer

Exhibit A

FINANCIAL STATEMENTS

MedVector Corp
Comparative Profit and Loss
For the Years Ended 12/31/20 and 12/31/19

	2020	2019
Income		
Total Income	\$0.00	\$0.00
Expenses		
Bank Service Charges	\$159.00	\$240.00
Consulting Fees	\$180,000.00	\$240,015.00
Data Service	\$468.00	\$818.00
Dues/Subscriptions	\$2,624.26	\$558.78
Finance Charges	\$3,136.75	\$707.92
Gasoline	\$418.99	\$459.28
Interest	\$6,803.72	\$21,602.00
Legal Fees	\$11,476.50	\$1,065.00
Licenses/Filings	\$45.00	\$45.00
Lodging	\$2,368.43	\$1,600.62
Meals	\$217.76	\$2,029.13
Office Supplies	\$2,641.54	\$1,286.63
Parking	\$54.75	\$110.50
Professional Fees	\$79,240.31	\$50,707.69
Promotional	\$9,804.88	
Prototype	\$20,337.46	\$165,076.13
Raise Consultant		\$17,500.00
Shipping and Postage	\$27.90	\$491.55
Software Expense	\$967.29	\$287.94
Tax Payments		\$225.00
Telephone	\$439.38	
Transportation	\$12.12	\$1,060.01
Travel Expenses		\$6,569.90
Web Hosting	\$401.75	
Web Services	\$567.95	
Total Expenses	\$322,213.74	\$512,456.08
Net Operating Income	(\$322,213.74)	(\$512,456.08)

MedVector Corp
Balance Sheet
As of December 31, 2020

	As of 12/31/20	As of 12/31/19
ASSETS		
Current Assets		
Bank Accounts		
Checking	170,947.22	26,997.61
Total Bank Accounts	\$ 170,947.22	\$ 26,997.61
Receivable from Start Engine	\$ 21,028.58	\$ 0.00
Total Current Assets	\$ 191,975.80	\$ 26,997.61
Fixed Assets		
Software	266,692.00	226,692.00
Total Fixed Assets	\$ 266,692.00	\$ 226,692.00
TOTAL ASSETS	\$ 458,667.80	\$ 253,689.61
LIABILITIES AND EQUITY		
Liabilities		
Current Liabilities		
Credit Cards	12,959.20	15,489.54
AP/Accrued Expenses	0.00	18,062.46
Total AP & Accruals	\$ 12,959.20	\$ 33,552.00
Other Current Liabilities		
Loan Payable	300,000.00	175,000.00
Total Other Current Liabilities	\$ 300,000.00	\$ 175,000.00
Total Current Liabilities	\$ 312,959.20	\$ 208,552.00
Total Liabilities	\$ 312,959.20	\$ 208,552.00
Equity		
Preferred Stock	105.00	105.00
Common Stock	500.00	500.00
Additional Paid in Capital	1,291,476.73	868,692.00
Retained Earnings	-1,146,373.13	-824,159.39
Total Equity	\$ 145,708.60	\$ 45,137.61
TOTAL LIABILITIES AND EQUITY	\$ 458,667.80	\$ 253,689.61

CERTIFICATION

I, Ian Leaman, Principal Executive Officer of MedVector Corp, hereby certify that the financial statements of MedVector Corp included in this Report are true and complete in all material respects.

Ian Leaman

Principal Executive Officer